65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

Schuette, Wolfgang; Schneider, Claus-Peter; Engel-Riedel, Walburga; Schumann, Christian; Kohlhaeufl, Martin; Serke, Monika Heidi Ursel; Hoeffken, Gert; Kortsik, Cornelius; Reck, Martin

Schuette, Wolfgang; Schneider, Claus-Peter; Engel-Riedel, Walburga; Schumann, Christian; Kohlhaeufl, Martin; Serke, Monika Heidi Ursel; Hoeffken, Gert; Kortsik, Cornelius; Reck, Martin.

Afiliación

Schuette W; Department of Internal Medicine II, Hospital Martha-Maria Halle-Doelau, Halle.
Schneider CP; Department of Pneumonology, Central Hospital, Bad Berka.
Engel-Riedel W; Department of Internal Medicine, DRK Manniske Hospital, Bad Frankenhausen.
Schumann C; Cologne Clinics, Merheim Lung Hospital, Cologne.
Kohlhaeufl M; Pneumonology, Department of Internal Medicine II, University Hospital Ulm.
Serke MHU; Clinic for Pneumology, Thoracic Oncology, Sleep, and Respiratory Critical Care, Kempten-Oberallgäu.
Hoeffken G; Center of Pneumonology and Chest Surgery, Hospital Schillerhoehe, Gerlingen.
Kortsik C; Pneumonology, Lung Clinics, Hemer.
Reck M; Center of Pneumonology, Chest and Vascular Surgery, Specialty Hospital Coswig, Coswig.

Lung Cancer (Auckl) ; 8: 217-229, 2017.

Article en En | MEDLINE | ID: mdl-29158696

Palabras clave

NSCLC; bevacizumab; carboplatin; elderly patients; pemetrexed

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Lung Cancer (Auckl) Año: 2017 Tipo del documento: Article